{"store":{"baseInfo":{"podcastTitle":"Rheumnow Podcast","slug":"rheumnow","podcastDescription":"Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com","podcastLogo":"https://pbcdn1.podbean.com/imglogo/image-logo/3681760/avatars-WU0yPZs9aq9zc0Tz-z65PkA-original.jpg","podcastShareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/image-logo/3681760/avatars-WU0yPZs9aq9zc0Tz-z65PkA-original_1200x628.jpg?s=3ce85dbda92e7c4bd28ec15975aace37&e=jpg","podcastUrl":"https://rheumnow.podbean.com","podcastCanSearched":true,"feedUrl":"https://feed.podbean.com/rheumnow/feed.xml","theme":"frontrow3","podcastDeepLink":"https://www.podbean.com/pw/pbblog-xt4xy-382de0?from=usersite","removePodbeanBranding":"no","brandingLogo":null,"timeZone":{"timeZoneId":11,"gmtAdjustment":"GMT-06:00","useDaylightTime":1,"value":-6,"text":"(GMT-06:00) Central Time (US & Canada)","daylightStartTime":"Second Sunday Of March +2 Hours","daylightEndTime":"First Sunday Of November +2 Hours","timezone":"America/Chicago"},"podcastDownloads":1247674,"totalEpisodes":968,"showComments":true,"iOSAppDownloadLink":null,"customizeCssUrl":null,"androidAppDownloadLink":null,"showPostShare":true,"showLike":true,"author":"Dr. Cush","enableEngagementStats":true,"shareEmbedLink":"https://admin5.podbean.com/embed.html?id=pbblog-xt4xy-382de0-playlist","language":"en","sensitivitySessionExpireTime":3600,"podcastApps":[{"name":"Apple Podcasts","link":"https://podcasts.apple.com/us/podcast/rheumnow-podcast/id1100856378","image":"https://pbcdn1.podbean.com/fs1/site/images/admin5/apple-podcast.png","title":null},{"name":"YouTube","link":"https://www.youtube.com/playlist?list=PLbd4uixNDSBSfsg-dooZsOEbAQ2pdXRBj","image":"https://pbcdn1.podbean.com/fs1/site/images/admin5/youtube_logo.png","title":null},{"name":"Podbean App","link":"https://www.podbean.com/pw/pbblog-xt4xy-382de0?from=usersite","image":"https://pbcdn1.podbean.com/fs1/site/images/admin5/podbean-app.png","title":null},{"name":"Spotify","link":"https://open.spotify.com/show/4Mjzj5jiwUqOzlhEOjKEjN","image":"https://pbcdn1.podbean.com/fs1/site/images/admin5/spotify.png","title":null}],"components":{"base":[{"id":"MainStyle","val":"light"},{"id":"Font","val":"Open Sans"},{"id":"SecondaryFont","val":"Lato"},{"id":"PlayerColor","val":"#ff6d00"},{"id":"PlayerStyle","val":"player1"},{"id":"PlayerWave","val":"show"},{"id":"Favicon","val":"https://www.podbean.com/images/favicon.ico"},{"id":"CookiesNotice","val":"hide"},{"id":"CookiesNoticeContent","val":"

Cookies Notice

This website uses cookies to improve your experience while you navigate through the website. By using our website you agree to our use of cookies.

"}],"home-header":[{"id":"HomeHeaderTextColor","val":"#ffffff"},{"id":"BackgroundImage","val":"https://mcdn.podbean.com/mf/web/k3w3iv/6-RheumNow.jpg"},{"id":"BackgroundImageForMobile","val":null}],"episode-list":[{"id":"EpisodeListType","val":"list"},{"id":"EpisodesPerPage","val":10},{"id":"EpisodeStats","val":"show"}],"navigation":[{"id":"NavigationFontColor","val":"#FFFFFF"},{"id":"NavigationBackgroundColor","val":"#000000"},{"id":"NavigationSearch","val":"show"},{"id":"NavigationLinks","val":[{"id":"Home","type":"Link","value":"/","text":"Home","subitems":[]},{"id":"Subscribe","type":"Link","value":"https://www.podbean.com/site/podcatcher/index/blog/JLwo3t2gI3G","text":"Subscribe","subitems":[]},{"id":"Profile","type":"Link","value":"https://www.podbean.com/user-x7Myrh7gupo","text":"Profile","subitems":[]}]}],"footer":[{"id":"FooterType","val":"Footer1"},{"id":"FooterFontColor","val":"#ffffff"},{"id":"FooterBackgroundColor","val":"#000000"},{"id":"FooterCopyright","val":"All rights reserved"},{"id":"SocialMediaLinks","val":{"facebook_username":"","twitter_username":"","instagram_username":"","youtube_username":"","linkedin_username":""}}],"customize-container1":[],"customize-container2":[]},"allLinks":[],"mainStylesDefaultSettings":null,"defaultCustomizeComponents":null,"scripts":["https://www.googletagmanager.com/gtag/js?id=G-D92H42VZJG","\n window.dataLayer = window.dataLayer || [];\n function gtag(){dataLayer.push(arguments);}\n gtag('js', new Date());\n\n gtag('config', 'G-D92H42VZJG',{'allow_enhanced_conversions':true});\n"],"metas":null,"appConfig":{"package":"com.podbean.app.podcast","app_store_id":973361050,"app_name":"Podbean","scheme":"podbean"},"customizeCss":null,"canEditCss":null,"enableJsCodeInCustomizeContent":false,"enabledIframeCodeInCustomizeContent":true,"sectionMaxCount":10,"enableEditorLink":true,"enableEditCookiesNotice":true,"siteRedirectToFeed":false,"podcatcherRssUrl":"https://www.podbean.com/site/podcatcher/index/blog/JLwo3t2gI3G","showFeed":true,"showTopBar":true,"enableWebSiteLike":true,"organizationName":null,"organizationPageLink":null},"backToListUrl":"/","tinymceLoaded":false,"listEpisodes":[],"userLikedEpisodes":[],"userLikeCheckedEpisodes":[],"topBarIframeLoaded":false,"listTotalCount":0,"listTotalPage":0,"listPage":0,"listType":"all","listValue":"","listName":"","pageLoading":false,"apiBaseUrl":"https://rheumnow.podbean.com","apiCommonParams":{"t":"687cfc08","clientSignature":"b87eec85a42bf6b8d551c7c9492d708d","u":null,"customizing":null},"apiCommonHeaders":{},"comments":[],"commentsTotalCount":0,"commentsTotalPage":0,"commentsPage":1,"commentEpisodeId":"pb17999734-azzyt","episode":{"id":"pb17999734","idTag":"azzyt","title":"ACR2021 - Day5a","logo":"https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog3681760/Copy_of_ACR_podcast_1__mvhif7_300x300.jpg","shareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/ep-logo/pbblog3681760/Copy_of_ACR_podcast_1__mvhif7_1200x628.jpg?s=62e850bb0b11b009b7b8d9f9b258341d&e=jpg","largeLogo":"https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog3681760/Copy_of_ACR_podcast_1__mvhif7.jpg","previewContent":null,"content":"

Tofacitinib and Malignancy Risk: Dr. Seoyoung Kim
Potpourri of Biosimilar Trials: Dr. Jonathan Kay
Closing a Chapter: Interview with the 84th ACR President 2020-2021, Kathryn Dao

","publishTimestamp":1636587558,"duration":1724,"mediaUrl":"https://mcdn.podbean.com/mf/web/zgncqi/ACR2021_-_Day5a6y6nk.mp3","mediaType":"audio/mpeg","shareLink":"https://admin5.podbean.com/embed.html?id=pb-azzyt-112a776","likedCount":0,"deepLink":"https://www.podbean.com/ew/pb-azzyt-112a776","transcriptUrl":null,"permalink":"/e/acr2021-day5a/","downloadLink":"https://www.podbean.com/media/share/pb-azzyt-112a776?download=1","fallbackResource":null,"fallbackResourceMimetype":null,"downloadCount":2766,"status":"publish","hasMoreContent":false,"chaptersUrl":null,"explicit":false},"episodeShareLink":null,"deepLink":"https://www.podbean.com/ew/pb-azzyt-112a776","playlist":{"episodes":[],"current":0,"start":0,"stop":0,"playing":true,"playerLoading":true,"playbackRate":1,"playbackRateIndex":1},"toasts":[],"confirm":null,"customizeEditorFormZIndex":999,"lastRequestTime":null,"validateChangesOnBeforeunload":true,"windowWidth":1000,"VITE_FS1_CDN_URL_PREFIX":"https://pbcdn1.podbean.com/fs1","reloadStats":false,"userIdEncrypted":null,"userProfilePicture":null,"username":null,"isVerified":false,"loadUserInfo":false,"loginUrl":"https://www.podbean.com/site/user/login?return=https%253A%252F%252Frheumnow.podbean.com%252Fe%252Facr2021-day5a%252F&rts=3607a28e16913cbf2e1f01ae32c01cb8f6f19f54","recaptchaV3Loaded":false,"recaptchaV2Loaded":false,"likesLoaded":false,"commentLikeMap":{},"commentOffset":0},"episode":{"id":"pb17999734","idTag":"azzyt","title":"ACR2021 - Day5a","logo":"https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog3681760/Copy_of_ACR_podcast_1__mvhif7_300x300.jpg","shareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/ep-logo/pbblog3681760/Copy_of_ACR_podcast_1__mvhif7_1200x628.jpg?s=62e850bb0b11b009b7b8d9f9b258341d&e=jpg","largeLogo":"https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog3681760/Copy_of_ACR_podcast_1__mvhif7.jpg","previewContent":null,"content":"

Tofacitinib and Malignancy Risk: Dr. Seoyoung Kim
Potpourri of Biosimilar Trials: Dr. Jonathan Kay
Closing a Chapter: Interview with the 84th ACR President 2020-2021, Kathryn Dao